Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

Anifrolumab (anifrolumab) is an antagonist human monoclonal antibody that targets interferon α receptor 1 (IFNAR1). Anifrolumab has been developed to treat autoimmune diseases and is currently in clinical trials. To decipher the molecular basis of its mechanism of action, we engaged in multiple epit...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Li, Oganesyan, Vaheh, Wu, Herren, Dall’Acqua, William F, Damschroder, Melissa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622752/
https://www.ncbi.nlm.nih.gov/pubmed/25606664
http://dx.doi.org/10.1080/19420862.2015.1007810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622752/
https://www.ncbi.nlm.nih.gov/pubmed/25606664
http://dx.doi.org/10.1080/19420862.2015.1007810

Ejemplares similares